Economic Impact of Pulmonary Drugs on Direct Costs of Stable Chronic Obstructive Pulmonary Disease

References

• Strassels S A, Smith D H, Sullivan S D, Mahajan P S. The costs of treating COPD in the United States. Chest 2001; 119: 344–352, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Sullivan S D, Ramsey S D, Lee T A. The economic burden of COPD. Chest 2000; 117: 5s–9s, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• The COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52(suppl 5)S1–S28
   PubMed Web of Science ®Google Scholar
• Siafakas N M, Vermeire P, Pride N B, Paoletti P, Gibson J, Howard P. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). A consensus statement of the European Respiratory Society. Eur Respir J 1995; 8: 1398–1420, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77–S120, [CSA]
   PubMed Web of Science ®Google Scholar
• Pauwels R A, Buist A S, Calverley P MA, Jenkins C R, Hurd S S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163: 1256–1276, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Barberà J A, Peces‐Barba G, Agustí A GN, Izquierdo J L, Monsó E, Montemayor T, Viejo L. Guía clínica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica. Arch Bronconeumol 2001; 37: 297–316, [CSA]
   PubMed Web of Science ®Google Scholar
• Grupo DAFNE. Costes directos de la bronquitis crónica en atención primaria. Análisis de un estudio prospectivo. Aten Primaria 2000; 27: 388–393, [CSA]
   Google Scholar
• Ruiz I, Cía M A, Aznar M T, Company V, Orozco A. Análisis del coste farmacéutico en el GRD‐88: enfermedad pulmonar obstructiva crónica. Farm Hosp 1996; 20: 49–54
   Google Scholar
• Figueras M, Brosa M, Gisbert R. El coste de la bronquitis crónica en España. Enfoque incidencia. Rev Esp Farmacoeconomía 1999; 2: 33–43
   Google Scholar
• de Miguel Díez J, Izquierdo Alonso J L, Molina París J, Rodríguez González‐Moro J M, de Lucas Ramos P, Gaspar Alonso‐Vega G. Fiabilidad del diagnóstico de la EPOC en atención primaria y neumología en España. Factores predictivos. Arch Bronconeumol 2003; 39: 203–208, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Bestall J C, Paul E A, Garrod R, Garnham R, Jones P W, Wedzicha A. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581–586, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ferrer M, Alonso J, Prieto L, Plata V, Monso E, Marrades R, Aguar M C, Khalaf A, Anto J M. Validity and reliability of the St George's respiratory questionnaire after adaptation to a different language and culture: the Spanish example. Eur Respir J 1996; 9: 1160–1166, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Vademecum Internacional. Medicom, MadridSpain 2000
   Google Scholar
• Sobradillo Peña V, Miratvilles M, Gabriel R, Jiménez‐Ruiz C A, Villasante C, Masa J F, Viejo J L, Fernández‐Fau L. Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiologic study. Chest 2000; 118: 981–989, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Stang P, Lydick E, Silberman C, Kempel A, Keating E T. The prevalence of COPD. Using smoking rates to estimate disease frequency in the general population. Chest 2000; 117: 354s–359s, [PUBMED], [INFOTRIEVE], [CROSSREF]
   Web of Science ®Google Scholar
• Miravitlles M. Evaluación económica en la EPOC. Arch Bronconeumol 2001; 37(suppl. 2)38–42
   Google Scholar
• Izquierdo J L. The burden of COPD in Spain: results from the confronting COPD survey. Respir Med 2003; 97(suppl. C)S61–S69, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Burge P S, Calverley P MA, Jones P W, Spencer S, Anderson J A, Maslen T K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease. The ISOLDE trial. BMJ 2000; 320: 1297–1303, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902–1909, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Niewoehner D E. Impact of drug classes used in COPD on outcome measures other than exacerbations. Eur Respir J 2002; 12: 11–12
   Google Scholar
• Wedzicha J A. Impact of drug classes used in COPD exacerbations. Eur Respir J 2002; 12: 13–14
   Google Scholar
• D'Urzo A D, De Salvo M C, Ramirez‐Rivera A, Almeida J, Sichletidis L, Rapatz G, Kottkis J. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3‐week, randomized, double‐blind, within‐patient multicenter study. Chest 2001; 119: 1347–1356, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sin D D, Man S F. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter?. Eur Respir J 2003; 21: 260–266, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002; 166: 1358–1363, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74–81, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mahler D A, Donohue J F, Barbee R A, Goldman M D, Gross N J, Wisniewski M E. Eficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957–965, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dhal R, Greefhorst L, Nowak D, Nonikov V, Byrne A M, Thomson M H, Till D, Della Cioppa G. Inhaled formeterol dry powder versus ipratropium bromide in chorinc obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778–784, [CSA]
   PubMed Web of Science ®Google Scholar
• Rennard S I, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, Wiesniewski M, Rickard K. Use of long‐acting inhaled beta‐2‐adrenergic agonists, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1087–1092, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Grandjean E M, Berthet P, Ruffmaun R, Leueuberger P. Efficacy of oral long‐term N‐acetylcysteine in chronic bronchopulmonary disease: a meta‐analysis of published double‐blind, placebo‐controlled clinical trials. Clin Ther 2000; 22: 209–221, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar